Measles Vaccine in HCW

• Status: Suspended
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kasr El Aini Hospital

Criteria

Inclusion Criteria:

• Age 18-50 years old

• Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion Criteria:

• acute severe illness

• recent receipt of a blood product

• history of thrombocytopenia

• Pregnant females

• any chronic medical condition

• Any participant receiving any immune suppressive medication

• Immunocompromised staff

• Participants who have egg allergy

• Participants who care for immune compromised hosts

• Participants who test positive for COVID-19 serology prior to randomization